Difference between revisions of "Binimetinib (Mektovi)"
Jump to navigation
Jump to search
m |
m |
||
| Line 12: | Line 12: | ||
==Also known as== | ==Also known as== | ||
*'''Code names:''' ARRY-162, ARRY-438162, MEK162 | *'''Code names:''' ARRY-162, ARRY-438162, MEK162 | ||
| − | *'''Brand names:''' | + | *'''Brand names:''' Mektovi |
[[Category:Drugs]] | [[Category:Drugs]] | ||
Revision as of 16:40, 17 May 2022
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Encorafenib (Braftovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Based on COLUMBUS)
Also known as
- Code names: ARRY-162, ARRY-438162, MEK162
- Brand names: Mektovi